[
    [
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)拟转让一无血清贴壁培养技术",
            "features": {
                "keywords": [
                    "万泰生物",
                    "无血清贴壁培养技术",
                    "技术转让"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "万泰生物(603392.SH)拟转让一无血清贴壁培养技术",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物：将获得基于CHO ZN?ZF-修饰细胞系的新冠病毒蛋白扩增纯化筛选和生产技术",
            "features": {
                "keywords": [
                    "万泰生物",
                    "新冠病毒蛋白",
                    "CHO ZN?ZF-修饰细胞系",
                    "生产技术"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "万泰生物：将获得基于CHO ZN?ZF-修饰细胞系的新冠病毒蛋白扩增纯化筛选和生产技术",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)年度归母净利润同比增长224.13%至6.77亿元 每10股送4股派2.5元",
            "features": {
                "keywords": [
                    "万泰生物",
                    "净利润增长",
                    "分红方案"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "万泰生物(603392.SH)年度归母净利润同比增长224.13%至6.77亿元 每10股送4股派2.5元",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)拟续聘容诚会计师事务所为2021年度财务报告及内部控制审计机构",
            "features": {
                "keywords": [
                    "万泰生物",
                    "容诚会计师事务所",
                    "审计机构"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物：2020年净利润同比增长224% 拟10送4派2.5元",
            "features": {
                "keywords": [
                    "万泰生物",
                    "净利润增长",
                    "分红方案"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)：将获得基于CHO ZN?ZF-修饰细胞系的新冠病毒蛋白扩增纯化筛选和生产技术",
            "features": {
                "keywords": [
                    "万泰生物",
                    "新冠病毒蛋白",
                    "CHO ZN?ZF-修饰细胞系",
                    "生产技术"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "万泰生物(603392.SH)：将获得基于CHO ZN?ZF-修饰细胞系的新冠病毒蛋白扩增纯化筛选和生产技术",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)：与养生堂拟签订技术许可成本分摊协议",
            "features": {
                "keywords": [
                    "万泰生物",
                    "养生堂",
                    "技术许可",
                    "成本分摊协议"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)：拟将基于U-2 OS细胞的无血清贴壁培养技术及知识产权转让给杭州养生堂",
            "features": {
                "keywords": [
                    "万泰生物",
                    "杭州养生堂",
                    "无血清贴壁培养技术",
                    "知识产权转让"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "万泰生物(603392.SH)：2021年度拟向相关金融机构申请合计不超过9.4亿元综合授信额度",
            "features": {
                "keywords": [
                    "万泰生物",
                    "金融机构",
                    "综合授信额度"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "万泰生物(603392.SH)：2021年度拟向相关金融机构申请合计不超过9.4亿元综合授信额度",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "中信证券：五粮液、万泰生物等5股的4月解禁市值超百亿元 解禁",
            "features": {
                "keywords": [
                    "中信证券",
                    "五粮液",
                    "万泰生物",
                    "解禁市值"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]